Recent literature on partial agonists has Recent literature on partial agonists has generated interest in their therapeutic generated interest in their therapeutic potential in schizophrenia. This has been potential in schizophrenia. This has been driven, in part, by the recent approval of driven, in part, by the recent approval of the dopamine (D2) receptor partial agonist the dopamine (D2) receptor partial agonist aripiprazole in the USA and Europe. In aripiprazole in the USA and Europe. In comparison with conventional and atypical comparison with conventional and atypical antipsychotics that mediate their therapeuantipsychotics that mediate their therapeutic effects by D2 receptor blockade, aripitic effects by D2 receptor blockade, aripiprazole has a unique mechanism of action. prazole has a unique mechanism of action. However, the concept of partial agonists However, the concept of partial agonists for the treatment of schizophrenia is not for the treatment of schizophrenia is not entirely novel, since aripiprazole is one of entirely novel, since aripiprazole is one of several members of this class of drug. This several members of this class of drug. This editorial reviews the neurochemistry of editorial reviews the neurochemistry of dopamine in schizophrenia and discusses dopamine in schizophrenia and discusses the theoretical importance of partial agonthe theoretical importance of partial agonism as a mechanism for the treatment of ism as a mechanism for the treatment of this illness. We also summarise the historithis illness. We also summarise the historical information on previous trials of partial cal information on previous trials of partial agonists in schizophrenia and evaluate agonists in schizophrenia and evaluate other dopamine receptor partial agonists other dopamine receptor partial agonists that are currently under development. that are currently under development.
Two fundamental properties of a drug Two fundamental properties of a drug determine its effect on a receptor: affinity, determine its effect on a receptor: affinity, the propensity of a drug to form a reversithe propensity of a drug to form a reversible complex with its receptor, and efficacy ble complex with its receptor, and efficacy (or intrinsic activity), the ability of a drug (or intrinsic activity), the ability of a drug to produce a functional response (Stephento produce a functional response (Stephenson, 1956; Ariens & Simonis, 1964) . For son, 1956; Ariens & Simonis, 1964) . For a given receptor, a drug can produce a a given receptor, a drug can produce a maximal response (full agonist) or have maximal response (full agonist) or have no functional effect (full antagonist). Full no functional effect (full antagonist). Full agonists are traditionally naturally occuragonists are traditionally naturally occurring compounds (e.g. dopamine) and full ring compounds (e.g. dopamine) and full antagonists are chemical entities produced antagonists are chemical entities produced by pharmaceutical chemists. In reality, the by pharmaceutical chemists. In reality, the majority of chemically related drugs acting majority of chemically related drugs acting at a receptor produce a spectrum of at a receptor produce a spectrum of functional responses that lie between full functional responses that lie between full agonism and full antagonism (Ariens, agonism and full antagonism (Ariens, 1964) . These drugs are termed 'partial 1964) . These drugs are termed 'partial agonists' because they have a lower agonists' because they have a lower intrinsic activity than full agonists. Partial intrinsic activity than full agonists. Partial agonists can elicit different receptor reagonists can elicit different receptor responses depending on their environment: sponses depending on their environment: in the presence of agonists with higher in the presence of agonists with higher intrinsic activity, partial agonists can intrinsic activity, partial agonists can demonstrate antagonist properties by demonstrate antagonist properties by blocking access to the receptor, but on their blocking access to the receptor, but on their own they will act as agonists (Fig. 1) . own they will act as agonists (Fig. 1 ). There are numerous reports of partial agoThere are numerous reports of partial agonists that act at the D2 receptor; those of renists that act at the D2 receptor; those of relevance to the treatment of schizophrenia levance to the treatment of schizophrenia are discussed in detail below. are discussed in detail below.
WHY IS A PARTIAL AGONIST WHY IS A PARTIAL AGONIST OF THEORETICAL INTEREST OF THEORETICAL INTEREST IN SCHIZOPHRENIA? IN SCHIZOPHRENIA?
The original dopamine hypothesis of The original dopamine hypothesis of schizophrenia proposed an excess of dopaschizophrenia proposed an excess of dopaminergic activity as the fundamental minergic activity as the fundamental neurochemical abnormality in the disorder neurochemical abnormality in the disorder (Carlsson & Lindqvist, 1963) . This was (Carlsson & Lindqvist, 1963) . This was based in part on the observation that based in part on the observation that typical antipsychotics such as chlorpromatypical antipsychotics such as chlorpromazine alleviated schizophrenia symptoms by zine alleviated schizophrenia symptoms by antagonising D2 receptors. Hence, dopaantagonising D2 receptors. Hence, dopamine receptor antagonists were considered mine receptor antagonists were considered the ideal therapeutic intervention in schizothe ideal therapeutic intervention in schizophrenia. In later years, the pharmacology of phrenia. In later years, the pharmacology of atypical antipsychotic agents such as clozaatypical antipsychotic agents such as clozapine and quetiapine led to a reassessment of pine and quetiapine led to a reassessment of these assumptions; atypicals demonstrated these assumptions; atypicals demonstrated relatively low affinities for dopamine receprelatively low affinities for dopamine receptors, but were also effective in the treatment tors, but were also effective in the treatment of schizophrenia (Pilowsky of schizophrenia (Pilowsky et al et al, 1992; , 1992; Kapur Kapur et al et al, 2000) . Atypical antipsychotics , 2000) . Atypical antipsychotics are superior to conventional antipsychotics are superior to conventional antipsychotics in the treatment of negative symptoms and in the treatment of negative symptoms and are less likely to cause extrapyramidal sideare less likely to cause extrapyramidal sideeffects (Kerwin & Osborne, 2000) , which effects (Kerwin & Osborne, 2000) , which has been attributed to their targeting of has been attributed to their targeting of neurotransmitter systems other than dopaneurotransmitter systems other than dopamine, in particular the serotonergic system mine, in particular the serotonergic system (Meltzer, 1999) . Thus, the search for (Meltzer, 1999) . Thus, the search for relevant drug targets was broadened to relevant drug targets was broadened to encompass other neurotransmitter recepencompass other neurotransmitter receptors; however, this approach has met with tors; however, this approach has met with modest success. It is apparent, though, that modest success. It is apparent, though, that all effective antipsychotics to date incorpoall effective antipsychotics to date incorporate D2 receptor antagonism in their rate D2 receptor antagonism in their mechanism of action; therefore, the current mechanism of action; therefore, the current drug discovery process aims to identify drug discovery process aims to identify drugs that primarily target the dopaminerdrugs that primarily target the dopaminergic system with greater therapeutic efficacy gic system with greater therapeutic efficacy (Kapur & Mamo, 2003) . When considering (Kapur & Mamo, 2003) . When considering the potential benefits of dopamine receptor the potential benefits of dopamine receptor partial agonists in the treatment of schizopartial agonists in the treatment of schizophrenia, two functional aspects of the phrenia, two functional aspects of the dopaminergic system require consideration: dopaminergic system require consideration: the postulated reciprocal dysregulation of the postulated reciprocal dysregulation of cortical and subcortical dopamine systems, cortical and subcortical dopamine systems, and the role of dopamine autoreceptors in and the role of dopamine autoreceptors in schizophrenia. schizophrenia.
DUAL PATHOLOGY DUAL PATHOLOGY
The original dopamine hypothesis for The original dopamine hypothesis for schizophrenia was based on the belief that schizophrenia was based on the belief that dopamine only innervated subcortical dopamine only innervated subcortical regions, and that these regions were overregions, and that these regions were overstimulated by excessive dopamine transstimulated by excessive dopamine transmission (Seeman & Lee, 1975; Creese mission (Seeman & Lee, 1975; Creese et al et al, 1976) . However, advances in bio-, 1976) . However, advances in biochemical and behavioural techniques led chemical and behavioural techniques led to the identification of additional cortical to the identification of additional cortical dopamine projections (Thierry dopamine projections (Thierry et al et al, 1973) , 1973) which responded in an opposite way to subwhich responded in an opposite way to subcortical dopamine systems: loss of frontal cortical dopamine systems: loss of frontal cortical dopamine function increased motor cortical dopamine function increased motor activity, in direct contrast to the observaactivity, in direct contrast to the observations following stimulation of dopamine tions following stimulation of dopamine receptors in extrapyramidal or mesolimbic receptors in extrapyramidal or mesolimbic regions (Carter & Pycock, 1979) . This regions (Carter & Pycock, 1979) . This seminal study and subsequent animal lesion seminal study and subsequent animal lesion experiments showed an opposite and reciexperiments showed an opposite and reciprocal regulation of cortical and subcortical procal regulation of cortical and subcortical dopamine systems, leading the authors to dopamine systems, leading the authors to propose that the fundamental neurochempropose that the fundamental neurochemical lesion in schizophrenia involved a ical lesion in schizophrenia involved a deficit in frontal cortical dopamine and an deficit in frontal cortical dopamine and an increase in subcortical dopamine function increase in subcortical dopamine function (Pycock (Pycock et al et al, 1980 (Pycock et al et al, , 1980a . ). Following these early reports, neuroFollowing these early reports, neuroimaging studies and neuropsychological imaging studies and neuropsychological tests on people with schizophrenia demontests on people with schizophrenia demonstrated impaired functioning of the frontal strated impaired functioning of the frontal lobe (hypofrontality) (Weinberger & Berlobe (hypofrontality) (Weinberger & Berman, 1996) , and a correlation with negative man, 1996), and a correlation with negative symptoms (Andreasen symptoms (Andreasen et al et al, 1992) and , 1992) and reduced dopaminergic activity (Weinberger reduced dopaminergic activity (Weinberger et al et al, 1988; Egan , 1988; Egan et al et al, 2001) . Furthermore, , 2001 ). Furthermore, cortical D1 receptor levels cortical D1 receptor levels are reduced in are reduced in patients with schizophrenia (Abi Dhargam patients with schizophrenia (Abi Dhargam & Moore, 2003) . In contrast to the findings & Moore, 2003) . In contrast to the findings in the frontal lobe, amphetamine-induced in the frontal lobe, amphetamine-induced excess release of dopamine in the striatum excess release of dopamine in the striatum (subcortical region) of patients with schizo-(subcortical region) of patients with schizophrenia compared with controls indicates a phrenia compared with controls indicates a hyperactive subcortical dopamine system in hyperactive subcortical dopamine system in schizophrenia (Breier schizophrenia (Breier et al et al, 1997) . Overac-, 1997) . Overactivity of the striatum was also associated tivity of the striatum was also associated with positive symptoms of schizophrenia with positive symptoms of schizophrenia (Breier (Breier et al et al, 1997) . , 1997). Thus, numerous studies on schizoThus, numerous studies on schizophrenia patients support the initial concept phrenia patients support the initial concept of Pycock and colleagues and a subsequent of Pycock and colleagues and a subsequent revised dopamine hypothesis of schizorevised dopamine hypothesis of schizophrenia, which proposed that hyperactive phrenia, which proposed that hyperactive mesolimbic (subcortical) dopamine tracts mesolimbic (subcortical) dopamine tracts contributed to the positive symptoms of contributed to the positive symptoms of schizophrenia and underactive mesocortical schizophrenia and underactive mesocortical (cortical) dopamine pathways played a (cortical) dopamine pathways played a part in negative symptoms and cognitive part in negative symptoms and cognitive impairment (Weinberger, 1987) . This posimpairment (Weinberger, 1987) . This postulated imbalance of dopamine function tulated imbalance of dopamine function in frontal and subcortical regions may in frontal and subcortical regions may be be a relevant therapeutic target in schizoa relevant therapeutic target in schizophrenia. Hence, a dopamine receptor phrenia. Hence, a dopamine receptor partial agonist (bearing in mind that partial partial agonist (bearing in mind that partial agonism is a relative concept) could act agonism is a relative concept) could act as a dopamine stabiliser by increasing as a dopamine stabiliser by increasing dopamine activity in the frontal cortex dopamine activity in the frontal cortex and diminishing hyperactive dopamine and diminishing hyperactive dopamine systems in subcortical regions. systems in subcortical regions.
AUTORECEPTORS AUTORECEPTORS
Dopamine autoreceptors may form an Dopamine autoreceptors may form an integral part of the therapeutic action of integral part of the therapeutic action of partial agonists in schizophrenia. Localised partial agonists in schizophrenia. Localised to terminals and dendrites of dopaminerto terminals and dendrites of dopaminergic neurons, dopamine autoreceptors (D2 gic neurons, dopamine autoreceptors (D2 and D3 receptors) exert a negative feedand D3 receptors) exert a negative feedback control on dopamine release and/ back control on dopamine release and/ or synthesis, subsequently reducing postor synthesis, subsequently reducing postsynaptic activity (Elsworth & Roth, 1997) . synaptic activity (Elsworth & Roth, 1997) . Dysregulation of neurotransmitter release Dysregulation of neurotransmitter release by dopamine autoreceptors could contriby dopamine autoreceptors could contribute to the postulated imbalance of cortibute to the postulated imbalance of cortical and subcortical dopamine function in cal and subcortical dopamine function in schizophrenia; for example, increased schizophrenia; for example, increased dopamine release due to the reduced dopamine release due to the reduced activity of dopamine autoreceptors might activity of dopamine autoreceptors might be one source of hyperactivity in subcortibe one source of hyperactivity in subcortical systems. Thus, partial agonists that cal systems. Thus, partial agonists that display affinity for dopamine autodisplay affinity for dopamine autoreceptors are potential stabilisers of receptors are potential stabilisers of dysregulated dopamine release in schizodysregulated dopamine release in schizophrenia (Grunder phrenia (Grunder et al et al, 2003) . However, , 2003) . However, it has been suggested that dopamine autoit has been suggested that dopamine autoreceptor antagonists (sulpiride and amisulreceptor antagonists (sulpiride and amisulpride) also stabilise dopamine systems in pride) also stabilise dopamine systems in schizophrenia by increasing dopamine schizophrenia by increasing dopamine release and selectively blocking D2 and release and selectively blocking D2 and D3 receptors in the limbic system D3 receptors in the limbic system (Kerwin, 2000) . (Kerwin, 2000) .
PARTIAL AGONISTS : PARTIAL AGONISTS : OLD AND NEW OLD AND NEW
The concept of partial agonists in the The concept of partial agonists in the correction of dysfunctional cortical and correction of dysfunctional cortical and subcortical connectivity in schizophrenia subcortical connectivity in schizophrenia dates back to the 1970s. Dopamine recepdates back to the 1970s. Dopamine receptor partial agonists, by virtue of their tor partial agonists, by virtue of their unique mechanism of action, potentially unique mechanism of action, potentially represent a distinct class of atypical antirepresent a distinct class of atypical antipsychotics. All clinically effective antipsypsychotics. All clinically effective antipsychotics mediate their therapeutic effects by chotics mediate their therapeutic effects by blockade of D2 receptors; partial agonists blockade of D2 receptors; partial agonists are postulated to improve symptoms by staare postulated to improve symptoms by stabilising dysregulated cortical and subcortibilising dysregulated cortical and subcortical dopamine systems without generating cal dopamine systems without generating the side-effects (movement disorders and the side-effects (movement disorders and hyperprolactinaemia) that are associated hyperprolactinaemia) that are associated with non-specific D2 receptor blockade of with non-specific D2 receptor blockade of the nigrostriatal and tuberoinfundibular the nigrostriatal and tuberoinfundibular pathways (Richelson, 1999) . pathways (Richelson, 1999) .
One well-known partial agonist for One well-known partial agonist for the the treatment of schizophrenia was ( treatment of schizophrenia was (7 7)-)-3-(3-hydroxyphenyl)-3-(3-hydroxyphenyl)-N N-n-propylpiperidine, -n-propylpiperidine, known known as ( as (7 7)-3PPP or preclamol. This )-3PPP or preclamol. This compound targets D2-like receptor subcompound targets D2-like receptor subtypes and is selective for the dopamine types and is selective for the dopamine autoreceptor (Clark autoreceptor (Clark et al et al, 1985; Chio , 1985; Chio et et al al, 1994) . Placebo-controlled studies indi-, 1994) . Placebo-controlled studies indicated rapid improvements in positive and cated rapid improvements in positive and negative symptoms without the generation negative symptoms without the generation of motor side-effects (Lahti of motor side-effects (Lahti et al et al, 1998) . , 1998). However, this effect was not sustained However, this effect was not sustained beyond 1 week, possibly owing to desensitibeyond 1 week, possibly owing to desensitisation of the dopamine autoreceptor. Other sation of the dopamine autoreceptor. Other dopamine partial agonists that have underdopamine partial agonists that have undergone trials in schizophrenia include talipexgone trials in schizophrenia include talipexole (B-HT 920), roxindole (EMD 49980) ole (B-HT 920), roxindole (EMD 49980) and SDZ-HDC 912, but their effects on and SDZ-HDC 912, but their effects on the symptoms of schizophrenia were, at the symptoms of schizophrenia were, at best, similar to conventional antipsychotics best, similar to conventional antipsychotics or not sustained at therapeutic doses (Ohor not sustained at therapeutic doses (Ohmori mori et al et al, 1993; Wetzel , 1993; Wetzel et al et al, 1994) . This , 1994) . This variability in therapeutic effects may relate variability in therapeutic effects may relate to differences in the intrinsic activity of to differences in the intrinsic activity of each partial agonist at dopamine receptors each partial agonist at dopamine receptors (Tamminga, 2002) . However, two recent (Tamminga, 2002) . However, two recent dopamine receptor partial agonists (aripidopamine receptor partial agonists (aripiprazole and bifeprunox) are promising prazole and bifeprunox) are promising 8 8 et al,1964) . In the absence of ,1964). In the absence of the full agonist, the partial agonist behaves as an agonist (squares), but produces a lower maximal response than the full agonist, the partial agonist behaves as an agonist (squares), but produces a lower maximal response than the full agonist. At higher concentrations of the full agonist (triangles), the partial agonist acts as an antagonist. the full agonist. At higher concentrations of the full agonist (triangles), the partial agonist acts as an antagonist. , 2002) . Additional evidence of aripiprazole's partial tional evidence of aripiprazole's partial agonist properties was gained from animal agonist properties was gained from animal models of dopamine hyperactivity and models of dopamine hyperactivity and hypoactivity: aripiprazole demonstrated hypoactivity: aripiprazole demonstrated antagonism of D2 receptors by suppressing antagonism of D2 receptors by suppressing apomorphine-induced stereotypy (dopaapomorphine-induced stereotypy (dopamine hyperactivity model), and D2 agonist mine hyperactivity model), and D2 agonist properties by blocking enhanced dopamine properties by blocking enhanced dopamine synthesis in rats treated with reserpine synthesis in rats treated with reserpine (dopamine hypoactivity model) (Kikuchi (dopamine hypoactivity model) (Kikuchi et al et al, 1995) . The stabilising effect of , 1995). The stabilising effect of aripiprazole on the dopamine system was aripiprazole on the dopamine system was attributed to its targeting of presynaptic attributed to its targeting of presynaptic 
CONCLUSIONS CONCLUSIONS
Unlike the conventional antipsychotic Unlike the conventional antipsychotic agents, modern atypical antipsychotics agents, modern atypical antipsychotics have a lower propensity to cause extrapyrhave a lower propensity to cause extrapyramidal side-effects and to improve negative amidal side-effects and to improve negative symptoms. Atypical antipsychotics demonsymptoms. Atypical antipsychotics demonstrate affinity for dopamine, serotonin and strate affinity for dopamine, serotonin and other neurotransmitter systems, but their other neurotransmitter systems, but their precise mechanism of action is unknown. precise mechanism of action is unknown. Several hypotheses have arisen to attempt Several hypotheses have arisen to attempt to characterise the 'atypicality' of a drug, to characterise the 'atypicality' of a drug, including a high 5-HT including a high 5-HT 2A 2A /D2 binding ratio /D2 binding ratio and fast dissociation from D2 receptors and fast dissociation from D2 receptors (Meltzer (Meltzer et al et al, 1989; Kapur & Seeman, , 1989; Kapur & Seeman, 2001 ). The D2 receptor partial agonists 2001). The D2 receptor partial agonists represent a class of drugs that may have represent a class of drugs that may have novel atypical properties. The therapeutic novel atypical properties. The therapeutic benefits of these drugs may reflect their benefits of these drugs may reflect their action as dopamine system stabilisers in action as dopamine system stabilisers in the presence of a potential cortical and the presence of a potential cortical and subcortical dopamine imbalance in schizosubcortical dopamine imbalance in schizophrenia. All antipsychotic drugs produce phrenia. All antipsychotic drugs produce adverse effects and are associated with variadverse effects and are associated with variable response to treatment. Consequently, able response to treatment. Consequently, there is still a requirement for effective, safe there is still a requirement for effective, safe and well-tolerated drugs for treating the and well-tolerated drugs for treating the symptoms of schizophrenia. The reviewed symptoms of schizophrenia. The reviewed evidence suggests a promising future for evidence suggests a promising future for dopamine receptor partial agonists in the dopamine receptor partial agonists in the treatment of patients with schizophrenia. treatment of patients with schizophrenia.
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